5-Ethynyl-1-(4-thio-β-D-arabinofuranosyl)uracil | 135123-31-8

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 核苷和核苷酸类似物
• 英文名称: 5-Ethynyl-1-(4-thio-β-D-arabinofuranosyl)uracil
• 英文别名: 1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)thiolan-2-yl]-5-ethynylpyrimidine-2,4-dione
• CAS: 135123-31-8
• 化学式: C₁₁H₁₂N₂O₅S
• 分子量: 284.293
• InChiKey: SJGGXCJITFYLGX-BDNRQGISSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  135
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• Treatment of EBV and KHSV infection and associated abnormal cellular proliferation
  申请人：——

  公开号：US20030176392A1

  公开（公告）日：2003-09-18

  A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

  提供了一种用于治疗、预防和/或预防寄主，特别是感染了爱泼斯坦-巴尔病毒（EBV）的人类的方法和组合物，包括向寄主施用有效量的5-取代尿嘧啶核苷或其药学上可接受的盐或前药，可选地还包括药学上可接受的稀释剂或赋形剂。
• Treatment of EBV and KHSV Infection and Associated Abnormal Cellular Proliferation
  申请人：Schinazi Raymond F.

  公开号：US20100168052A1

  公开（公告）日：2010-07-01

  A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

  本发明提供了一种用于治疗、预防和/或预防宿主，特别是人类，感染EB病毒（EBV）的方法和组合物，其中包括在药物接受者中给予有效量的5-取代尿嘧啶核苷或其药学上可接受的盐或前药，可选地在药学上可接受的稀释剂或赋形剂中。
• TREATMENT OF EBV AND KHSV INFECTION AND ASSOCIATED ABNORMAL CELLULAR PROLIFERATION
  申请人：GILEAD PHARMASSET LLC

  公开号：US20140336143A1

  公开（公告）日：2014-11-13

  A method and composition for the treatment, prevention and/or prophylaxis of a host, and in particular, a human, infected with Epstein-Barr virus (EBV), is provided that includes administering an effective amount of a 5-substituted uracil nucleoside or its pharmaceutically acceptable salt or prodrug, optionally in a pharmaceutically acceptable diluent or excipient.

  提供一种用于治疗、预防和/或预防寄主，特别是人类，感染EB病毒（EBV）的方法和组合物，其中包括在药学上可接受的稀释剂或赋形剂中投与有效量的5-取代尿嘧啶核苷或其药学上可接受的盐或前药。
• Further antiviral pyrimidine nucleosides
  申请人：THE UNIVERSITY OF BIRMINGHAM

  公开号：EP0421777A1

  公开（公告）日：1991-04-10

  Pyrimidine 4′-thionucleosides of the formula (I) where B¹ is a pyrimidine base; and either (a) R² is hydrogen and R³ is hydroxy or fluoro, or (b) R² is hydroxy and R³ is hydrogen, hydroxy or fluoro, or (c) R² is fluoro and R³ is hydrogen or hydroxy, or (d) R² and R³ together form a carbon-carbon bond; and physiologically functional derivatives thereof and processes for their production. Preferably, the base B¹ is of the formula (II) wherein Y is hydroxy or amino, monoalkylamino or dialkylamino; and X is halogen, alkoxy, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, amino, monoalkylamino, dialkylamino, cyano or nitro. The compounds are useful in the treatment of viral infections.

  式(I)的嘧啶-4′-硫代核苷 其中 B¹ 是嘧啶碱； (a) R² 是氢，R³ 是羟基或氟、 或 (b) R² 是羟基，R³ 是氢、羟基或氟、 或 (c) R² 是氟，R³ 是氢或羟基、 或 (d) R² 和 R³ 共同形成碳-碳键；以及其生理功能衍生物及其生产工艺。碱 B¹ 最好为式 (II) 其中 Y 是羟基或氨基、单烷基氨基或二烷基氨基；X 是卤素、烷氧基、烷基、卤代烷基、烯基、卤代烯基、炔基、氨基、单烷基氨基、二烷基氨基、氰基或硝基。这些化合物可用于治疗病毒感染。
• US7211570B2
  申请人：——

  公开号：US7211570B2

  公开（公告）日：2007-05-01